* hypersensitivity to the active substance or to any of the excipients * pregnancy or breastfeeding woman * known hepatic failure (pt \<50%, factor v \< 50%) * last known plasma total bilirubin \> 21 μmol/l * lactate level \> 4 mmol/l * alt and ast levels greater than 3 times the upper limit * pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction * history of pulmonary embolism * diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized * paco2 \> 45 mmhg * exacerbation of asthma or chronic respiratory failure * cardiogenic pulmonary oedema * systolic blood pressure of 90 mmhg or less, or use of vasopressors * urgent need for endotracheal intubation at the discretion of the treating physician * do-not-intubate order or estimated life expectancy less than 6 months * participation in another interventional research

* hypersensitivity to the active substance or to any of the excipients * pregnancy or breastfeeding woman * known hepatic failure (pt \<50%, factor v \< 50%) * last known plasma total bilirubin \> 21 μmol/l * lactate level \> 4 mmol/l * alt and ast levels greater than 3 times the upper limit * pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction * history of pulmonary embolism * diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized * paco2 \> 45 mmhg * exacerbation of asthma or chronic respiratory failure * cardiogenic pulmonary oedema * systolic blood pressure of 90 mmhg or less, or use of vasopressors * urgent need for endotracheal intubation at the discretion of the treating physician * do-not-intubate order or estimated life expectancy less than 6 months * participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt and ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt and ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt and ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current airvm covid protocol, version 5.0 of 12/01/2021 9/47 this document is the property of drci/ap-hp. all reproduction is strictly prohibited. hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt and ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current airvm covid protocol, version 5.0 of 12/01/2021 9/47 this document is the property of drci/ap-hp. all reproduction is strictly prohibited. hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt/ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current airvm covid protocol, version 5.0 of 12/01/2021 9/47 this document is the property of drci/ap-hp. all reproduction is strictly prohibited. hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - last known plasma total bilirubin > 21 μmol/l - lactate level > 4 mmol/l - alt/ast levels greater than 3 times the upper limit - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current airvm covid protocol, version 5.0 of 12/01/2021 9/47 this document is the property of drci/ap-hp. all reproduction is strictly prohibited. hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - known plasma total bilirubin > 21 µmol/l during hospitalization - lactate level > 4 mmol/l - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research

- hypersensitivity to the active substance or to any of the excipients - pregnancy or breastfeeding woman - known hepatic failure (pt <50%, factor v < 50%) - known plasma total bilirubin > 21 µmol/l during hospitalization - lactate level > 4 mmol/l - pulmonary hypertension (paps ≥37 mmhg and/or vmaxit ≥ 2,9 m/s) or right ventricular dysfunction - history of pulmonary embolism - diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized - paco2 > 45 mmhg - exacerbation of asthma or chronic respiratory failure - cardiogenic pulmonary oedema - systolic blood pressure of 90 mmhg or less, or use of vasopressors - urgent need for endotracheal intubation at the discretion of the treating physician - do-not-intubate order or estimated life expectancy less than 6 months - participation in another interventional research